Medical Retina Monitoring Pathway for patients on Hydroxychloroquine or Chloroquine.

Medical Retina Monitoring

The Royal College of Ophthalmologists recommends a baseline assessment and annual screening for retinal toxicity for patients on long-term therapy of Hydroxychloroquine and Chloroquine. This service allows for the community retinal screening of patients within optical practice.

The LOCSU pathway and clinical management guidelines offer an integrated service delivery model with data collection in primary care and virtual review by a consultant ophthalmologist. Aligning to the RCOphth guidelines, this allows for patients to be seen within the community in a consultant-led service.

The service aims to identify patients at risk of vision loss through screening.

LOCSU support for the pathway

LOCSU has developed a range of downloadable support for members of Local Optical Committees who want to introduce these pathways in their area, including:

Medical Retina Monitoring pathway diagram

Medical Retina Monitoring Clinical Management Guidelines

Other Useful Documents:

Hydroxychloroquine and Chloroquine Retinopathy: Recommendations on Screening – Royal College of Ophthalmologists guidance

Patient Leaflet – Eye screening for patients taking hydroxychloroquine – Macular Society Royal College of Ophthalmologists